Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vestas signs orders for 220 MW in Argentina

Genneia S.A., Argentina’s largest wind energy supplier in terms of installed capacity, has placed a firm and unconditional order for a total of 62 V126-3.45 wind turbines. The turbines will be installed in wind parks located close to Puerto Madryn in Chubut, one of the windiest regions in Argentina.    Walter Lanosa, CEO of Genneia S. A., said “Our long-lasting business relationship with Vestas is delivering very good results for both companies. We started making business together when we signed Rawson I&II in 2010, Argentina’s largest wind park at the time. In 2016 we signed the

Vestas receives 48 MW order in Greece

Vestas has received a firm and unconditional order for the 48 MW Petalas wind park in the region of Aitoloakarnania in western Greece. The order comprises 24 V100-2.0 MW turbines and was placed by Protergia S.A., a wholly-owned subsidiary of Mytilineos Holdings S.A. The contract includes supply and installation of the wind turbines as well as a 10-year Active Output Management 4000 (AOM4000) service agreement to maximise energy production at all times. Delivery of the wind turbines is expected to begin in the fourth quarter of 2017. “We are very happy to work once again, together with

Detection Technology Plc - Managers' Transactions

Detection Technology Plc Managers' Transactions 6 June 2017 at 14:30 (EEST) Detection Technology Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Hyvärinen, Kari Position: Other senior manager Issuer: Detection Technology Plc LEI: 743700IXKYKNXJ6BFL39 Notification type: INITIAL NOTIFICATION Reference number: 743700IXKYKNXJ6BFL39_20170606120454_2 ____________________________________________ Transaction date: 2017-06-05 Venue: FIRST NORTH FINLAND (FNFI) Instrument type: SHARE

Decisions by the Shareholders’ Meeting of the merged Ahlstrom Corporation

AHLSTROM-MUNKSJÖ OYJ, STOCK EXCHANGE RELEASE JUNE 6, 2017 at 13:15 CEST The Shareholders’ Meeting of the merged Ahlstrom Corporation was held in Helsinki today. The Shareholders’ Meeting adopted the Financial Statements for 2016 and for the period January 1-March 31, 2017 (Final Accounts). The Shareholders’ Meeting also discharged Ahlstrom Corporation’s former members of the Board of Directors and the President and CEO from liability. Ahlstrom Corporation was merged into Ahlstrom-Munksjö Oyj on April 1, 2017. Helsinki, June 6, 2017AHLSTROM CORPORATIONBoard of Directors

Changes in Metsä Board Corporation’s Corporate Management Team

M.Sc. (Tech.) Harri Pihlajaniemi has been appointed Metsä Board Corporation’s, a part of Metsä Group, SVP, Production, and a member of the Corporate Management Team latest as of 6 September 2017. He moves to Metsä Board from Stora Enso, where he has held several production related managerial positions since 2004.Metsä Board Corporation Stock Exchange Release 6 June 2017 at 2 pm EEST M.Sc. (Tech.) Harri Pihlajaniemi has been appointed Metsä Board Corporation’s, a part of Metsä Group, SVP, Production, and a member of the Corporate Management Team latest as of 6 September 2017. He moves to

Ponsse introduces new technology for productivity and ergonomics

Ponsse offers the broadest range of products in the market for cut-to-length logging. The new PONSSE model series will be introduced at the Elmia Wood 2017 exhibition in its full glory. Solutions that focus especially on improving the operator's performance and comfort supplement the new model series.The PONSSE Scorpion harvester, the flagship of the new PONSSE model series, was launched at the 2013 Elmia Wood exhibition. The launch gave start to a complete modernisation of the model series, focusing specifically on improved productivity and ergonomics alongside higher serviceability. So

EVRY – Announcement of terms of initial public offering

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE LOCAL SECURITIES LAWS OR REGULATIONS OF SUCH JURISDICTION. With reference to the announcement of 23 May 2017, EVRY ASA ("EVRY", the "Company", OSE ticker code: "EVRY") has now approved the terms of and resolved to commence its initial public offering of its ordinary shares (the "IPO").The Offer Shares (as defined below) are expected to be sold at a price between NOK

Restamax Plc: JUHA HELMINEN APPOINTED CEO OF RESTAMAX PLC

Restamax PlcSTOCK EXCHANCE RELEASE 6 JUNE 2017 at 12:00 JUHA HELMINEN APPOINTED CEO OF RESTAMAX PLC The Board of Directors of Restamax Plc has appointed Juha Helminen M.Sc.(Tech.) (born 1977) CEO of Restamax and a member of the Executive Team from 1 September 2017. Helminen will be responsible for the company's operations, result and development. Helminen is currently Vice President, Sales at Sinebrychoff. Helminen has solid experience of the brewery and restaurant sectors, from senior positions in business management both in Finland and abroad. Among other positions, during the

Valmet and MJB International in Dubai sign a cooperation agreement for gas turbine automation

Valmet Oyj's trade press release on June 6, 2017 at 11:00 a.m. EETValmet has signed a cooperation agreement for gas turbine automation with MJB International Ltd (MJBI), an independent total gas turbine service provider with main locations in Scotland, and Abu Dhabi and Dubai, UAE. According to the agreement, Valmet together with MJBI will develop triple modular redundant (TMR) gas turbine control systems as part of MJBI's gas turbine retrofit capabilities for customers around the world. "At Valmet, we have developed our capabilities and services in turbine automation systems for

SimCorp A/S – Share buyback program

On 27 February 2017 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 17.5m (approx. DKK 130.4m) in the period from 27 February 2017 to 23 August 2017. The following transactions have been executed under the program:     Date                 Number of shares Average Amount (DKK)

New possible target for cancer treatment

[PRESS RELEASE 2017-06-06] Scientists at Karolinska Institutet in Sweden report that cancer cells and normal cells use different ‘gene switches’ in order to regulate the expression of genes that control growth. In mice, the removal of a large regulatory region linked to different types of cancer caused a dramatic resistance to tumour formation, but did not affect normal cell growth. The findings, published in the scientific journal eLife, highlight the possibility of developing highly specific cancer drugs with fewer side effects.Humans have close to 20,000 genes to carry out all the

Urban transport cleans up its act - HSL and Stara shift to renewable fuels only

(UPM, Helsinki, 6 June 2017 at 09:00 EET) - Buses in the Helsinki region and most of machinery and trucks used by the City of Helsinki are switching to waste and residue-based biofuels. Helsinki Region Transport HSL, the City of Helsinki and the producers of renewable fuels involved in the project are all pioneers in carbon-neutral transport. The project is internationally significant. Commercial vehicles operated by the City of Helsinki and bus services commissioned by HSL will fully switch to renewable fuels by 2020. This is a pioneering project in global terms. The construction

BerGenBio’s selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017

Bergen, Norway, June 6 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, reported encouraging clinical and in vitro data with its lead, first-in-class Axl inhibitor, BGB324 in patients with high-risk Myeloid Dysplastic Syndrome (MDS) in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 in Chicago, IL.The clinical data presented at ASCO showed that BGB324 could be a promising novel treatment for patients with MDS. One

Finnair Traffic Performance in May 2017

Finnair Plc               Investor News             6 June 2017 at 09:00 am Number of passengers grew 9.4% and exceeded a million In May, Finnair's overall capacity measured in Available Seat Kilometres increased by 1.2 per cent year‐on‐year, and traffic measured in Revenue Passenger Kilometres grew by 12.8 per cent. The capacity operated with Finnair’s own fleet grew by 3.7 per cent year-on-year, while wet-lease operations decreased substantially. The number of passengers slightly exceeded a million and was 9.4 per cent more than a year ago. The passenger load factor rose by 8.4

NattoPharma Signs Technology Licensing Agreement with ZümXR

Provides exclusive use of proprietary encapsulation technology for Vitamin K2OSLO, NORWAY and METUCHEN, NJ (June 6, 2017) – NattoPharma has reached an accord with ZümXR that provides NattoPharma with the exclusive rights to add ZümXR’s proprietary, patented encapsulation technology to its Advance Delivery Platform™ (ADP) offering. ADP enables NattoPharma customers to incorporate MenaQ7® in a broad range of delivery applications, which answers the growing consumer demand for innovative alternative delivery vehicles. This trend is evident in the expanding options for consumers to meet

Pemamek to supply complete welding automation solution for ASM Industries

Portugal-based onshore and offshore application manufacturer, ASM Industries, has selected Pemamek to provide turnkey automated welding and production solution for manufacturing of tubular structures for offshore foundations. Comprehensive delivery Pemamek has won a notable contract to supply full-scope solution for the Portuguese offshore solutions manufacturer, ASM Marine. The company is very active in the field of offshore renewable and other offshore structural parts and is a part of ASM Industries Holding, a key-player in the field of renewable energy. The contract

AGM Statement

6 June 2017 Genel Energy plc AGM Statement Tony Hayward, Chairman of Genel Energy plc (‘Genel’ or ‘the Company’), will give the following update on the business at the Company’s Annual General Meeting, which is being held at 11.00am today at J.P. Morgan, 60 Victoria Embankment, London, EC4Y 0JP. "Genel has a clear strategic focus - maximising the generation of free cash flow from our oil assets, accelerating the recovery of the receivable for unpaid oil sales, and crystallising value from the KRI gas business. The Tawke field continues to perform in line with expectations,

Finnish 5G test networks are piloting the digital business and service models of the future

Finland’s 5G test networks are shifting their focus from technology development more towards large-scale service trials. The work continues in close cooperation with key vertical industry partners that, in the future, are planning to deploy their digital services on top of mobile network platforms.The new 5G network capabilities will be able to meet the varying requirements of different industrial use cases in addition to the traditional mobile broadband services offered to consumers today.”In practice, 5G networks significantly improve the adaptability, reliability and security of the

Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting

Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that it presented clinical data from the phase I/II clinical trial evaluating TG01 in resected pancreatic cancer in a poster presentation at the American Society of Clinical Oncology Annual Meeting 2017 (ASCO) on Saturday, June 3rd 2017. The study evaluated safety, immunological response and overall survival of TG01/GM-CSF and gemcitabine as an adjuvant therapy for treating

Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London

Oslo, Norway, 6 June 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces formal agenda for its Capital Markets Updates, to be hosted in Oslo on Thursday 8 June and in London on Monday 26 June 2017. The event in Oslo will commence at 9:00am CEST, and will also be webcasted. The event in London will commence at 12:30pm BST. Lunch will be served. The meetings, which will be open to analysts, brokers, investors and press, will include presentations from Targovax's senior

KONE to supply elevators and escalators for Funan DigitaLife Mall, a mixed-use development in Singapore

KONE Corporation, press release, June 6, 2017   KONE, a global leader in the elevator and escalator industry, has won an order to supply 69 elevators and escalators to Funan DigitaLife Mall, an integrated development located in Singapore and owned by CapitaLand Mall Trust. Designed as a unique lifestyle destination, Funan DigitaLife Mall will offer a new live-work-play paradigm that sparks inspiration and discovery for consumers.  The integrated development comprises of two premium Grade A office towers, a block of serviced residence and a retail component. KONE will

Lundbeck obtains rights to breakthrough research in Alzheimer’s disease

H. Lundbeck A/S (Lundbeck) has entered into an agreement with biotech company ImmunoBrain Checkpoint, Inc. (IBC) for the rights to IBC’s groundbreaking research in the treatment of Alzheimer’s disease. The research focuses on modifying antibodies currently used in cancer treatment for use in treating the debilitating brain disease which 48 million patients are estimated to suffer from[i]. A number expected to rapidly increase in the future.“IBC has a unique and innovative approach to this highly complex disease and the data generated until now are highly promising. We are delighted to take

There are no items matching the current filter
There are no more items matching the current filter
Back to top